Our global life sciences company brings diagnostic testing & drug development together. Explore what we do.
We are pleased to announce that we have made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause dystonia. Our Comprehensive Dystonia Panel now includes 192 genes and 5,048 pathogenic variants associated with conditions linked to dystonia. This panel includes mtDNA sequencing and deletion analysis with the option of adding HTT repeat expansion analysis, ensuring you are provided with the most comprehensive testing possible.
Understanding a comprehensive panel may not always be necessary, we updated 4 of our existing subpanels to cover more medically relevant genes and increase their clinical sensitivity. In addition, we have introduced a new Dopa-Responsive Dystonia panel to our portfolio.
All of our next-generation sequencing panels include single-exon resolution copy number analysis to provide you the most clinically sensitive testing possible.
June 19, 2020
Effective July 27, 2020 the MNG amino acid assays, Test Codes MET01, MET02, and MET03 will be performed by our Parent company, LabCorp, in its Burlington, NC laboratory.
October 24, 2019
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
October 1, 2019
Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.